Fig. 5

Macular topographic maps (left panels) and colour macular maps (right) to show the sustained reduction in central retinal thickness for more than 3 years after treatment with a single 0.2 μg/day FAc intravitreal implant in a patient with non-infectious intermediate uveitis. Images shown for a single patient eye where the FAc implant led to a sustained thinning of retinal thickness to below 250 μm (i.e. a dry retina) throughout the period between the 28th February 2014 and the 11th May 2017. During this period the eye did not require re-treatment until 42 months after receiving the first FAc implant. The patient had previously received therapy for chronic macular oedema for 4 years including multiple intravitreal triamcinolone or dexamethasone implants and systemic therapies (details of this patient are reported as case 4 in Weber et al. 2019 [10]